Optimizing doses of a first line chemotherapy treatment containing epirubicin, paclitaxel and capecitabine (TEX) in metastatic breast cancer.

被引：0
|
作者：
Einbeigi, Z
Bergström, D
Hatschek, T
Malmberg, M
机构：
[1] Sahlgrens Univ Hosp, S-41345 Gothenburg, Sweden
[2] Roche AB, Stockholm, Sweden
[3] Karolinska Hosp, S-10401 Stockholm, Sweden
[4] Helsingborg Hosp, Helsingborg, Sweden
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2003年 / 82卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
539
引用
收藏
页码：S131 / S131
页数：1
相关论文
共 50 条
  • [31] Gemcitabine and cisplatin combination chemotherapy as first-line treatment in patients with metastatic breast cancer.
    Alauddin, Z
    Shaharyar, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 56S - 56S
  • [32] Epirubicin (E), cisplatin (C) and capecitabine (X) in first-line chemotherapy for patients with advanced gastric cancer.
    Cho, EK
    Lee, WK
    Im, SA
    Lee, SN
    Park, SH
    Bang, SM
    Shin, DB
    Lee, JH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 331S - 331S
  • [33] Activity and safety of biweekly docetaxel plus capecitabine as first-line treatment for patients with metastatic breast cancer.
    Llorca, C
    Mayordomo, J
    Adrover, E
    Alvarez, I
    Madroñal, C
    Burillo, M
    Sanz, J
    Lorenzo, A
    Palombo, H
    Janariz, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 73S - 73S
  • [34] Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial
    C Pacilio
    A Morabito
    F Nuzzo
    A Gravina
    V Labonia
    G Landi
    E Rossi
    E De Maio
    M Di Maio
    G D'aiuto
    G Botti
    N Normanno
    P Chiodini
    C Gallo
    F Perrone
    A de Matteis
    [J]. British Journal of Cancer, 2006, 94 : 1233 - 1236
  • [35] Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial
    Pacilio, C
    Morabito, A
    Nuzzo, F
    Gravina, A
    Labonia, V
    Landi, G
    Rossi, E
    De Maio, E
    Di Maio, M
    D'Aiuto, G
    Botti, G
    Normanno, N
    Chiodini, P
    Gallo, C
    Perrone, F
    de Matteis, A
    [J]. BRITISH JOURNAL OF CANCER, 2006, 94 (09) : 1233 - 1236
  • [36] Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER-2 negative breast cancer.
    Altundag, Kadri
    Babacan, Taner
    Efe, Orhan
    Hasirci, Ahmet S.
    Demirci, Fatih
    Buyukhatipoglu, Hakan
    Balakan, Ozan
    Sarici, Furkan Saim
    Kertmen, Neyran
    Esin, Ece
    Akin, Serkan
    Ates, Ozturk
    Aksoy, Sercan
    Sever, Ali R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Docetaxel and carboplatin followed by sequential capecitabine as first line treatment in patients with locally advanced or metastatic breast cancer.
    Lorenzo, A.
    Modolell, A.
    Valero, P.
    Murillo, L.
    Garcia-Bueno, J. M.
    Yubero, A.
    Machengs, I. H.
    [J]. CANCER RESEARCH, 2009, 69 (02) : 202S - 202S
  • [38] Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine)
    Svensson, Helene
    Einbeigi, Zakaria
    Johansson, Hemming
    Hatschek, Thomas
    Brandberg, Yvonne
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2010, 123 (03) : 785 - 793
  • [39] Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine)
    Helene Svensson
    Zakaria Einbeigi
    Hemming Johansson
    Thomas Hatschek
    Yvonne Brandberg
    [J]. Breast Cancer Research and Treatment, 2010, 123 : 785 - 793
  • [40] Quality of life in women with metastatic breast cancer during nine months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine)
    Svensson, H.
    Einbeigi, Z.
    Johansson, H.
    Hatschek, T.
    Brandberg, Y.
    [J]. EJC SUPPLEMENTS, 2010, 8 (03): : 197 - 197
12345